睿知中国医院研究地图
候选清单

正在招募多发性骨髓瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由中国医学科学院血液病医院(血液学研究所)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07652905,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use effective contraception from the time of signing the informed consent form, throughout study treatment, and for at least 3 months after the last dose of study treatment.

    入选标准第 24 条

  3. Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;

    入选标准第 11 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.

    入选标准第 12 条

    White blood cell (WBC) count ≥1.5 × 10⁹/L;

    入选标准第 15 条

    Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L;

    入选标准第 16 条

    Hemoglobin ≥70 g/L;

    入选标准第 17 条

    Platelet count ≥50 × 10⁹/L;

    入选标准第 18 条

    At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;

    入选标准第 21 条

    At least 1 week between the last platelet transfusion and platelet count assessment at screening.

    入选标准第 22 条

  4. Pregnant or breastfeeding women.

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07652905,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able to understand and voluntarily sign a written informed consent form (ICF).
  2. Age 18 to 75 years.
  3. Newly diagnosed primary plasma cell leukemia (pPCL) according to International Myeloma Working Group (IMWG) criteria, defined as either:
  4. ≥5% circulating plasma cells on peripheral blood smear; or
  5. Absolute circulating plasma cell count >2 × 10⁹/L.
  6. Measurable disease, defined by at least one of the following:
  7. Serum M-protein ≥10 g/L as measured by serum protein electrophoresis (SPEP); for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead;
  8. Urine M-protein ≥200 mg/24 hours;
  9. If neither serum nor urine M-protein meets the above criteria, involved serum free light chain (FLC) ≥100 mg/L with an abnormal serum FLC ratio (normal range: 0.26-1.65).
  10. Adequate hepatic function, defined as:
  11. Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;
  12. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.
  13. Adequate renal function, defined as creatinine clearance ≥30 mL/min, calculated using the Cockcroft-Gault formula.
  14. Adequate hematologic function within 7 days prior to enrollment, defined as:
  15. White blood cell (WBC) count ≥1.5 × 10⁹/L;
  16. Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L;
  17. Hemoglobin ≥70 g/L;
  18. Platelet count ≥50 × 10⁹/L;
  19. Participants receiving hematopoietic growth factor support, including erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or thrombopoietic agents, must have a washout period of at least 2 weeks between the last administration of growth factor support and screening assessments.
  20. Participants receiving blood product transfusions must meet the following requirements:
  21. At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;
  22. At least 1 week between the last platelet transfusion and platelet count assessment at screening.
  23. Able and willing to receive protocol-recommended prophylactic anticoagulation therapy.
  24. Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use effective contraception from the time of signing the informed consent form, throughout study treatment, and for at least 3 months after the last dose of study treatment.

排除标准:Exclusion Criteria:

  1. Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or secondary plasma cell leukemia.
  2. Central nervous system (CNS) involvement or clinical evidence of leptomeningeal involvement.
  3. Known intolerance, hypersensitivity, allergy, or contraindication to CM336, isatuximab, bortezomib or lenalidomide.
  4. Severe and/or uncontrolled cardiovascular disease, including:
  5. Active infection, including:
  6. Concurrent active malignancy or any serious concomitant disease that, in the investigator's judgment, could compromise participant safety or interfere with study participation.
  7. Pregnant or breastfeeding women.
  8. Estimated life expectancy of less than 6 months.
  9. Active gastrointestinal disorders that may impair the participant's ability to swallow oral medication or may interfere with the absorption of study treatment.
  10. Major surgery within 2 weeks prior to enrollment (e.g., surgery requiring general anesthesia), incomplete recovery from prior surgery, or planned major surgery during study participation. Kyphoplasty and vertebroplasty are not considered major surgery. Participants undergoing procedures under local anesthesia may be eligible.
  11. Receipt of a live attenuated vaccine within 4 weeks before the first dose of study treatment.
  12. Any active severe psychiatric disorder, medical condition, symptom, or other circumstance that, in the investigator's judgment, may interfere with treatment, protocol compliance, or the ability to provide informed consent.
  13. Inability or unwillingness to provide written informed consent.

引自 ClinicalTrials.gov, NCT07652905, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07652905,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07652905